Indica Labs Announces Webinar for Late September
Indica Labs: Learn how HALO AI Apps can accelerate your life science research applications
Introducing HALO AI Apps for the Life Sciences
Date: 26 September 2024
Time: 8:00 – 9:00 PDT | 11:00 – 12:00 EDT | 16:00 – 17:00 BST
Location: Webinar
Summary
Join [Indica Labs] for this 1-hour webinar to see a live demonstration of the 11 new HALO AI Apps now available for life science research. In this webinar, Dr. Kate Lillard, Chief Scientific Officer at Indica Labs, will showcase the powerful image analysis capabilities across a variety of tissue types out-of-the-box and will demonstrate how the apps can be further trained, tuned, and improved upon by customers with their own images and data. Kate will also demonstrate how the HALO AI Apps are seamlessly integrated with HALO® image analysis modules to facilitate tumor-specific analysis of biomarker expression and investigate immune infiltration and spatial relationships between lymphocytes and cancer cells within the tumor microenvironment.
HALO AI Apps require HALO and HALO AI 4.0.5 or later.
Learning Objectives
- Learn about IHC & H&E HALO AI Apps for breast, colorectal, gastric, ovarian, head and neck squamous cells, non-small cell lung cancer, and pan-cancer applications
- Learn how pretrained HALO AI Apps can be used right out-of-the-box or further trained and optimized
- Discover how HALO AI Apps can be seamlessly integrated with HALO image analysis models for powerful image analysis functionality
Presenter
Dr. Kate Lillard
Chief Scientific Officer
Indica Labs
Kate Lillard received her PhD in Molecular Genetics and Biochemistry from the University of Cincinnati Medical Center, followed by a Howard Hughes postdoctoral fellowship at the University of Texas Southwestern Medical Center. While conducting research in the area of stem cell biology and oncology as a graduate and postdoctoral fellow, Dr. Lillard developed a keen interest in IHC which led to her joining Aperio in 2007 where she supported and then managed image analysis products for digital pathology. After acquisition of Aperio by Leica in late 2012, Dr. Lillard joined Indica Labs as Chief Scientific Officer where she supports, promotes, and helps guide the development of digital pathology image analysis solutions for the life sciences.
SOURCE: Indica Labs
